Frontiers in Rheumatoid Arthritis: Emerging Research and Unmet Needs in Pharmacologic Management

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) management has evolved with disease-modifying antirheumatic drugs (DMARDs).
• Despite advancements, many RA patients do not meet treatment goals, highlighting challenges in preclinical inflammatory arthritis, late-onset RA, and treatment-resistant RA.
• Current treat-to-target strategies face limitations in addressing specific RA patient phenotypes.

Purpose of the Study:

• To review recent clinical and translational research in RA over the last decade.
• To identify RA clinical phenotypes with inadequate response to guideline-directed therapy.
• To highlight precision medicine and real-world evidence (RWE) approaches for individualized RA care.

Main Methods:

• Review of peer-reviewed clinical and translational research in RA.
• Analysis of precision medicine strategies to characterize RA pathogenesis.
• Evaluation of real-world data from clinical practice and registries on DMARD therapy.

Main Results:

• Identified specific RA phenotypes that are therapeutically challenging.
• Precision medicine is beginning to inform tailored DMARD therapy for individual RA patients.
• Real-world evidence confirms long-term DMARD effectiveness, revises safety profiles, and estimates treatment costs.

Conclusions:

• Precision medicine and RWE offer opportunities to address unmet needs in RA care.
• Individualized, patient-centered care is advancing through these approaches.
• These strategies aim to improve disease control for RA patients who do not respond to current therapies.